Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides

https://doi.org/10.1016/0090-6980(76)90047-2Get rights and content

Abstract

Prostaglandin (PG) endoperoxides (PGG2 and PGH2) contract arterial smooth muscle and cause platelet aggregation. Microsomes from pig aorta, pig mesenteric arteries, rabbit aorta and rat stomach fundus enzymically transform PG endoperoxides to an unstable product (PGX) which relaxes arterial strips and prevents platelet aggregation. Microsomes from rat stomach corpus, rat liver, rabbit lungs, rabbit spleen, rabbit brain, rabbit kidney medulla, ram seminal vesicles as well as particulate fractions of rat skin homogenates transform PG endoperoxides to PGE- and PGF- rather than to PGX-like activity.

PGX differs from the products of enzymic transformation of prostaglandin endoperoxides so far identified, including PGE2, F, D2, thromboxane A2 and their metabolites.

PGX is less active in contracting rat fundic strip, chick rectum, guinea pig ileum and guinea pig trachea than are PGG2 and PGH2. PGX does not contract the rat colon.

PGX is unstable in aqueous solution and its anti-aggregating activity disappears within 0.25 min on boiling or within 10 min at 37° C.

As an inhibitor of human platelet aggregation induced in vitro by arachidonic acid PGX was 30 times more potent than PGE1. The enzymic formation of PGX is inhibited by 15-hydroperoxy arachidonic acid (IC50 = 0.48 μg/ml), by spontaneously oxidised arachidonic acid (IC50 <100 μg/ml) and by tranylcypromine (IC50 = 160 μg/ml).

We conclude that a balance between formation by arterial walls of PGX which prevents platelet aggregation and release by blood platelets of prostaglandin endoperoxides which induce aggregation is of the utmost importance for the control of thrombus formation in vessels.

References (47)

  • C.S. Kitchens et al.

    Ultrastructural changes of endothelium associated with thrombocytopenia

    Blood

    (1975)
  • A. Robert et al.

    Effect of prostaglandin E1 on gastric secretion and ulcer formation in the rat

    Gastroenterology

    (1968)
  • Y.H. Lee et al.

    Effects of oral administration of PGE2 on gastric secretion and experimental peptic ulcerations

    Prostaglandins

    (1973)
  • J.F. Mustard et al.

    Platelets, thrombosis and drugs

    Drugs

    (1975)
  • H. Heath et al.

    Platelet adhesiveness and aggregation in relation to diabetic retinopathy

    Diabetologia

    (1971)
  • H.C. Kwaan et al.

    Disseminated intravascular coagulation in diabetes mellitus, with reference to the role of increased platelet aggregation

    Diabetes

    (1972)
  • J. Sagel et al.

    Increased platelet aggregation in early diabetes mellitus

    Ann. Intern. Med.

    (1975)
  • E. Bologna

    Anti-hypertensive treatment and platelet aggregation

  • S. Lentini et al.

    Hypertension and platelet aggregation

  • K. Breddin et al.

    Is enhanced platelet aggregation a risk factor for thrombo-embolic complications in atherosclerosis?

  • A.J. Roy et al.

    Effects of platelet transfusions; plug formation and maintenance of vascular integrity

  • I. Aurnes

    Appearance of red cells in peripheral lymph during radiation-induced thrombocytopenia

    Acta Physiol. Scand.

    (1973)
  • M. Hamberg et al.

    Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides

  • Cited by (775)

    • Serelaxin: A Novel Therapeutic for Vascular Diseases

      2016, Trends in Pharmacological Sciences
    • Pharmacological modulation of fibrinolytic response - In vivo and in vitro studies

      2015, Pharmacological Reports
      Citation Excerpt :

      Since endothelium–blood platelets interaction plays a fundamental role in the regulation of haemostasis, besides fibrinolytic system we also focused on the involvement of platelets in discussed mechanisms. PGI2 in 1976 was described by Gryglewski et al. as a substance protecting vascular wall against deposition of platelets thrombi [6]. It is produced by an enzyme, prostacyclin endoperoxidase from cyclic endoperoxides in endothelium cells [7].

    • Coronary and muscle blood flow during physical exercise in humans; Heterogenic alliance

      2015, Pharmacological Reports
      Citation Excerpt :

      Since the coronary blood flow is responsible for about 80% of the O2 supply to the myocardium, while the remaining 20% is governed by arterial-venous difference in O2 content, a functionally efficient endothelium is required to meet the enhanced oxygen needed in the contracting heart and to limit the risk of metabolic instability that may ensue during exercise in pathological conditions. The endothelium represents a highly active autocrine, paracrine and endocrine organ synthetizing many vasoactive substances, including vasoconstrictors (thromboxane A2, endothelin-1, prostaglandin H2) and vasodilators such as nitric oxide (NO) [65], prostacyclin (PGI2) [66,67] and endothelium-derived hyperpolarizing factors (EDHF) [68]. The relative contribution of dilating and constricting substances to maintain vascular tone and adequate tissue perfusion during both rest and exercise depends on the vessel diameter and vascular bed.

    • On the Eicosanoid Trail with John Vane and Jack McGiff: 1974-1976. A personal reminiscence

      2015, Prostaglandins and Other Lipid Mediators
      Citation Excerpt :

      At the same time as these exciting developments in renal prostaglandin research, other major discoveries were emerging from the Prostaglandin group's labs. In 1976 Richard Gryglewski, Stuart Bunting, Salvador Moncada, Rod Flower and others discovered and characterised a novel prostaglandin produced from vascular tissue with striking biological properties [37], [30]). This compound, originally known as ‘prostaglandin X’ was subsequently identified and synthesised in conjunction with the Upjohn company and subsequently named prostacyclin [31].

    View all citing articles on Scopus
    View full text